Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 179

Sort by

Sort Order Select

Journal Articles

Consent to Future Use of Residual and Banked Specimens Among Adults with Hematologic Malignancies: Analyzing SWOG Clinical Trial Data from 2000-2024

Daniel J. Olivieri, Alexis Berridge-Green, Megan Othus, Anna B. Moseley, Jerald P. Radich, Anjali S. Advani, Harry P. Erba, Roland B. Walter

Blood (2024) 144 (Supplement 1): 2414.

https://doi.org/10.1182/blood-2024-199817

Published: 2024

Journal Articles

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Blood (2024) 144 (Supplement 1): 2426.

https://doi.org/10.1182/blood-2024-207278

Published: 2024

Journal Articles

Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG

Vivian M. Liu, Megan Othus, Rhonda E. Ries, Jasmine Naru, Era L. Pogosova-Agadjanyan, Frederick R. Appelbaum, Lan W. Beppu, Thomas R. Chauncey, Harry P. Erba, John E. Godwin, Matthew Fitzgibbon, Min Fang, Stanley C. Lee, Anna B. Moseley, Jerald P. Radich, Cheryl L. Willman, Feinan Wu, Soheil Meshinchi, Derek L. Stirewalt

Blood (2024) 144 (Supplement 1): 4309.

https://doi.org/10.1182/blood-2024-198506

Published: 2024

Journal Articles

Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2950.

https://doi.org/10.1182/blood-2024-194922

Published: 2024

Journal Articles

Novel Nilotinib Tablet Formulation: Pharmacokinetic Characterization and Effects of Food

Michael J. Mauro, Jerald P. Radich, Paras Jain, David Sequeira, Dan Douer

Blood (2024) 144 (Supplement 1): 5799.

https://doi.org/10.1182/blood-2024-194406

Published: 2024

Journal Articles

First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)

Jorge E. Cortes, Michael J. Mauro, Alexis Visotcky, Srinivas K Tantravahi, James E Thompson, Jay Yang, Arielle Baim, Yan Gao, Sonia Maldonado-Schmidt, Claire Olig, Kathryn E. Flynn, Jerald P. Radich, Ehab L. Atallah

Blood (2024) 144 (Supplement 1): 6601.

https://doi.org/10.1182/blood-2024-207884

Published: 2024

Journal Articles

Single-Cell Multi-Omic Analysis of AML MRD Reveals Differences in Clonal Architecture between Relapse and Non-Relapse Cases

Adam Sciambi, Daniel Mendoza, Kathryn Thompson, Lan W. Beppu, Benjamin Geller, Indira Krishnan, Lubna Nousheen, Shu Wang, Charlie Murphy, Jerald P. Radich, Todd E. Druley

Blood (2024) 144 (Supplement 1): 1568.

https://doi.org/10.1182/blood-2024-210840

Published: 2024

Journal Articles

Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)

Blood (2024) 144 (Supplement 1): 736.

https://doi.org/10.1182/blood-2024-210370

Published: 2024

Journal Articles

Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia

Blood (2024) 144 (Supplement 1): 993.

https://doi.org/10.1182/blood-2024-201881

Published: 2024

Journal Articles

Rapid Clinical Mutation Screening for AML Using the Genexus Platform

Shahanawaz Jiwani, Jerald P. Radich, Maria Saeed, Lauri Aicher, Ting-Chia Chang, Srikrishna Narava, Zaneta Holman, Lan Beppu, Olga Sala-Torra, Marvin Majano, Erin Taylor, Laura Yee, Jessica Li, Lisa McShane, Pooja CS Sanduria, Paul Mickey M. Williams, Cecilia C.S. Yeung

Blood (2023) 142 (Supplement 1): 2288.

https://doi.org/10.1182/blood-2023-188270

Published: 2023

Journal Articles

Successful Treatment-Free Remission in Low- and Middle-Income Countries

Jerald P. Radich, Ines Garcia Gonzalez, Alicia Annamalay, Geoff Cook, Isaac Jenkins, Flora Duarte, VP Gangadharan, Hemant Malhotra, Pankaj Malhotra, Karen Meliksetyan, Rafael Zuniga, Nicholas Anthony Othieno-Abinja, Jose Zarza, Pat Garcia-Gonzalez

Blood (2023) 142 (Supplement 1): 1808.

https://doi.org/10.1182/blood-2023-191049

Published: 2023

Journal Articles

Long-Term Follow up for SWOG 1318: Combination of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

Anjali S. Advani, Anna B Moseley, Kristen M. O'Dwyer, Brent L. Wood, Jae H. Park, Matthew J. Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab L. Atallah, Aaron T. Gerds, Susan M. O'Brien, Jane L. Liesveld, Megan Othus, Mark R. Litzow, Richard M Stone, Elad Sharon, Cecilia C.S. Yeung, Jerald P. Radich, Harry P. Erba

Blood (2023) 142 (Supplement 1): 1499.

https://doi.org/10.1182/blood-2023-180204

Published: 2023

Journal Articles

Does Detection of <20% Lymphoblasts in Patients with CML Herald Imminent Blast Crisis? a Study from BCR::ABL1 Pathology Group

Blood (2023) 142 (Supplement 1): 6364.

https://doi.org/10.1182/blood-2023-187020

Published: 2023

Journal Articles

Multiomic Single-Cell Sequencing May Distinguish BCR-ABL-Mutated Acute Myeloid Leukemia (AML) from Blast Crisis Chronic Myelogenous Leukemia (BC-CML)

Vanessa E. Kennedy, Cheryl A C Peretz, Andrew Koh, Elaine Tran, Dalia Dhingra, Saurabh Gulati, Adam Sciambi, Olga Sala-Torra, Lan Beppu, Aaron C. Logan, Alexander Perl, Wendy Stock, Geoffrey L Uy, Ann-Kathrin Eisfeld, Jerald P. Radich, Catherine C. Smith

Blood (2023) 142 (Supplement 1): 4334.

https://doi.org/10.1182/blood-2023-182454

Published: 2023

Journal Articles

High-Resolution Proximity-Guided Cytogenomics Improves Patient Stratification and Uncovers New Variants in Acute Myeloid Leukemia

Stephen Eacker, Maika Malig, Kyle Langford, Alexander Muratov, Mary Wood, Olga Sala-Torra, Shawn T Sullivan, Ivan Liachko, Cecilia C.S. Yeung, Jerald P. Radich

Blood (2023) 142 (Supplement 1): 5980.

https://doi.org/10.1182/blood-2023-190195

Published: 2023

Journal Articles

Characteristics and Prognostic Effects of DNMT3A Co-Mutations

Blood (2022) 140 (Supplement 1): 745–747.

https://doi.org/10.1182/blood-2022-162526

Published: 2022

Journal Articles

A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income

Jerald P. Radich, Chung Hoow Kok, Ekaterina Yu. Chelysheva, Jorge E. Cortes, Qian Jiang, Michael Mauro, Dragana Milojkovic, Beatriz Moiraghi, Franck E. Nicolini, Matilda Ongondi, Katia B Pagnano, Daniela Žácková, Delphine Rea, Nicola Evans, Timothy Hughes

Blood (2022) 140 (Supplement 1): 9617–9619.

https://doi.org/10.1182/blood-2022-165855

Published: 2022

Journal Articles

DNA Methylation Profiles Capture Clinical and Molecular Heterogeneity of MDS and Can be Harnessed for the Development of Robust Biomarkers Predictive of Response to Azacitidine

Qin Yang, Alice Brogi, Elizabeth A. Griffiths, Matilde Y Follo, Carlo Finelli, Jerald P. Radich, Michael J Rauh, Mikkael A. Sekeres, Rafael Bejar, Valeria Santini, Maria Ken E. Figueroa

Blood (2022) 140 (Supplement 1): 9769–9770.

https://doi.org/10.1182/blood-2022-163704

Published: 2022

Journal Articles

Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study

Michael Mauro, Alexis Visotcky, Kathryn E Flynn, Jerald P. Radich, Jay Yang, Vivian G. Oehler, Jorge E. Cortes, Vamsi K Kota, Srinivas K. Tantravahi, Arielle Baim, Mei-Jie Zhang, Alexander Hinman, Ehab L. Atallah, Kendra Sweet

Blood (2022) 140 (Supplement 1): 6765–6766.

https://doi.org/10.1182/blood-2022-160138

Published: 2022

Journal Articles

Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study

Ehab L. Atallah, Alexis Visotcky, Kathryn E Flynn, Mei-Jie Zhang, Jerald P. Radich, Jay Yang, Vivian G. Oehler, Srinivas K. Tantravahi, B. Douglas Douglas Smith, Javier Pinilla Ibarz, Kendra Sweet, Michael Mauro, Brian J. Druker, James E. Thompson, Sonia Maldonado-Schmidt, Arielle Baim, Charles A. Schiffer, Vamsi K. Kota, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 3885–3886.

https://doi.org/10.1182/blood-2022-160172

Published: 2022

NARROW

Consent to Future Use of Residual and Banked Specimens Among Adults with Hematologic Malignancies: Analyzing SWOG Clinical Trial Data from 2000-2024

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG

Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

Novel Nilotinib Tablet Formulation: Pharmacokinetic Characterization and Effects of Food

First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)

Single-Cell Multi-Omic Analysis of AML MRD Reveals Differences in Clonal Architecture between Relapse and Non-Relapse Cases

Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)

Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia

Rapid Clinical Mutation Screening for AML Using the Genexus Platform

Successful Treatment-Free Remission in Low- and Middle-Income Countries

Long-Term Follow up for SWOG 1318: Combination of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

Does Detection of <20% Lymphoblasts in Patients with CML Herald Imminent Blast Crisis? a Study from BCR::ABL1 Pathology Group

Multiomic Single-Cell Sequencing May Distinguish BCR-ABL-Mutated Acute Myeloid Leukemia (AML) from Blast Crisis Chronic Myelogenous Leukemia (BC-CML)

High-Resolution Proximity-Guided Cytogenomics Improves Patient Stratification and Uncovers New Variants in Acute Myeloid Leukemia

Characteristics and Prognostic Effects of DNMT3A Co-Mutations

A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income

DNA Methylation Profiles Capture Clinical and Molecular Heterogeneity of MDS and Can be Harnessed for the Development of Robust Biomarkers Predictive of Response to Azacitidine

Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study

Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only